Frontier Biotechnologies(SH:688221) Xin Lang Cai Jing·2026-01-23 05:22Group 1 - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. is a biopharmaceutical company focused on researching, developing, producing, and selling innovative drugs to meet significant unmet clinical needs, with a strong competitive edge in HIV long-acting treatment and immunotherapy [1] - The company has one patented anti-HIV drug that is already marketed globally and two drugs in clinical trials that are also patented or licensed [1] - The main revenue source for the company is from the drug Aikening, which accounts for 91.29% of total revenue, while other products contribute 8.71% [1] Group 2 - E Fund Medical Healthcare Industry Mixed A Fund (110023) has recently entered the top ten circulating shareholders of Frontier Biopharmaceuticals, holding 7.7173 million shares, which is 2.06% of the circulating shares [2] - The fund has achieved a year-to-date return of 7.11% and a one-year return of 36.28%, ranking 3214 out of 8847 and 3483 out of 8099 in its category, respectively [2] - The fund manager, Yang Zhenshao, has been in position for 9 years and 159 days, with a total asset scale of 7.952 billion yuan and a best return of 215.45% during his tenure [3] Group 3 - E Fund Medical Healthcare Industry Mixed A Fund (110023) has a significant holding in Frontier Biopharmaceuticals, with 7.7173 million shares representing 4.15% of the fund's net value, making it the seventh-largest holding [4] - The fund has realized a floating profit of approximately 10.1868 million yuan from its investment in Frontier Biopharmaceuticals [4]